All In Biotech

Drug Trial Radar · NCT03699475

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS

Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1

Actual

Start

Dec 27, 2018

Primary completion

Jul 23, 2019

Study completion Jul 23, 2019

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes

Interventions

  • rivogenlecleucelBiological

    Biological: T cells transduced with caspase 9 safety switch

  • rimiducidDrug

    administered to inactivate rivogenlecleucel in the event of GVHD

  • CyclophosphamideDrug

    GVHD prophylaxis

  • haplo-HSCTProcedure

    treatment for disease

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Experiencing 3 or More Dose Limiting Toxicities [Phase 2] Within a 100-day DLT Window After Receiving BPX-501Time frame: 100 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • TriStar Bone Marrow Transplant, LLC

    Nashville, Tennessee

  • Methodist Healthcare System of San Antonio Clinical Trials Office

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.